Xbrane Biopharma appoints Anders P. Wiklund as strategic advisor
Mr. Wiklund has throughout his long career in the Pharmaceutical and Biotechnology Industries, been involved as a dealmaker in numerous transactions. As CEO, Chairman or board member in both private and public companies in the USA and Europe, Mr. Wiklund has been actively involved in M&A transactions, out and in-licensing deals and private and public financing. He was also a cofounder of Esperion Therapeutics, which was sold for 1,3 Billion USD to Pfizer. He presently serves on the boards of EffRx Pharmaceuticals SA, Inspirion Delivery Technologies LLC, Life Medical AB and IRRAS AB
"We are very excited to have Anders P. Wiklund as a strategic advisor to Xbrane. His long experience in M&A and licensing in the Pharmaceutical sector will be of great value for Xbrane in the upcoming out-licensing of both Spherotide and Xlucane.", says Martin Åmark, Xbranes CEO.
"I am impressed both by the entrepreneurial spirit at Xbrane and its innovative, patented technology that has the promise of making the company a very important player in the Biosimilar space. I look forward with enthusiasm to work with the management of Xbrane, in this exciting phase of the company development, particularly regarding the global expansion and out-licensing of Xbranes leading products." says Anders P. Wiklund
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbranes's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd under the name XBRANE and Avanza Bank AB is Xbranes certified advisor. For more information see www.xbrane.com.
For further information, please contact:
Chief Executive Officer
M: +46 (0) 763-093 777
This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 23 December 2016.